Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-11T12:45:13.305Z Has data issue: false hasContentIssue false
  • English
  • Français

PILOTING INTERNATIONAL PRODUCTION OF RAPID RELATIVE EFFECTIVENESS ASSESSMENTS OF PHARMACEUTICALS

Published online by Cambridge University Press:  06 March 2015

Sarah Kleijnen ,
Iris Pasternack ,
Piia Rannanheimo ,
Jenni M Vuola ,
Marc Van de Casteele ,
Anna Bucsics ,
Isabelle Zahra Pulis ,
Rossella Di Bidino ,
Dario Sacchini  and
Simona Montilla
...Show all authors
Sarah Kleijnen
Affiliation:
Zorginstituut Nederland & Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciencesskleijnen@zinl.nl
Iris Pasternack
Affiliation:
Zorginstituut Nederland & Summaryx Ltd
Piia Rannanheimo
Affiliation:
Finnish Medicines Agency
Jenni M Vuola
Affiliation:
GlaxoSmithKline
Marc Van de Casteele
Affiliation:
Rijksinstituut voor ziekte- en invaliditeitsverzekering, Directie Farmaceutisch Beleid & KU Leuven
Anna Bucsics
Affiliation:
Hauptverband der Österreichischen Sozialversicherungsträger and University of Vienna
Isabelle Zahra Pulis
Affiliation:
Directorate for Pharmaceutical Affairs, Ministry for Energy and Health
Rossella Di Bidino
Affiliation:
HTA Unit, “A.Gemelli” Teaching Hospital
Dario Sacchini
Affiliation:
Institute of Bioethics, “Agostino Gemelli” School of Medicine” School of Medicine
Simona Montilla
Affiliation:
Italian Medicines Agency
Payam Abrishami
Affiliation:
Zorginstituut Nederland
Sylvana Magrin Sammut
Affiliation:
Directorate for Pharmaceutical Affairs, Ministry for Energy and Health
Luisa Anna Adele Muscolo
Affiliation:
Italian Medicines Agency
Pertti Happonen
Affiliation:
Finnish Medicines Agency
Wim G. Goettsch
Affiliation:
Zorginstituut Nederland & Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: This article describes the lessons learned from an international pilot assessment using the first version of the HTA Core Model® and Guidelines for rapid Relative Effectiveness Assessment (REA) of pharmaceuticals based on input from three different perspectives: the assessors, the users (health technology assessment organisations) and the marketing authorisation holder.

Methods: A pilot assessment was performed of pazopanib for the treatment of advanced or metastatic renal cell carcinoma for which 54 individuals from 22 EUnetHTA member organisations from 16 European countries gave their contribution. The work was divided in eight domain teams. Subsequently, results of these domain teams were synthesised in one pilot report. Feedback on the outcomes of the pilot was gathered throughout the project and through structured surveys.

Results: The first version of the assessment was produced in six months and consisted of 55 question and answer pairs, 8 domain reports and a synthesis section that combined the results from the different domains. The organisation of the pilot required intense coordination. Main points of criticism on the assessment were the lengthiness of the document and overlap of information throughout the assessment.

Conclusions: A reduction in the number of authoring organisations and individuals participating is necessary to avoid information overlap and increase efficiency in undertaking the assessment. Involving several organisations (e.g. five) in an in-depth review could still ensure the benefit of broad participation from various countries. The focus of a rapid REA should be on the first four domains of the Model.

Keywords

Technology assessmentComparative effectiveness researchPilot projectsInternational cooperation
Type
Theme Submissions
Information
International Journal of Technology Assessment in Health Care , Volume 30 , Issue 5 , November 2014 , pp. 521 - 529
Copyright
Copyright © Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Kleijnen, S, Goettsch, W, d’Andon, A, et al. EUnetHTA JA WP5: Relative Effectiveness Assessment (REA) of Pharmaceuticals. Background review. July 2011. http://eunethta.fedimbo.belgium.be/sites/5026.fedimbo.belgium.be/files/Final%20version%20of%20Background%20Review%20on%20Relative%20Effectiveness%20Assessment%2Bappendix.pdf (accessed September 19, 2013).Google Scholar
2. Hutton, J, Trueman, P, Facey, K. Harmonization of evidence requirements for health technology assessment in reimbursement decision making. Int J Technol Assess Health Care. 2008;24:511–517.CrossRefGoogle ScholarPubMed
3. High Level Pharmaceutical Forum 2005–2008. Conclusions and recommendations. 2008 http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/pharmaforum_final_conclusions_brochure_en.pdf (accessed September 19, 2013).Google Scholar
4. Kleijnen, S, George, E, Goulden, S, et al. Relative effectiveness assessment of pharmaceuticals: Similarities and differences in 29 jurisdictions. Value Health. 2012;15 (6):954–960.Google Scholar
5. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems. Official Journal L 040, 11/02/1989 P. 0008–0011.Google Scholar
6. Lampe, K, Mäkelä, M, Garrido, MV, et al. The HTA core model: A novel method for producing and reporting health technology assessments. Int J Technol Assess Health Care. 2009;25 (Suppl 2):9–20.Google Scholar
7. EUnetHTA Joint Action 1 WP5. Pazopanib for the treatment of advanced renal cell carcinoma Pilot assessment using the draft HTA Core Model for Rapid Relative Effectiveness Assessment model. December 2012 http://eunethta.fedimbo.belgium.be/sites/5026.fedimbo.belgium.be/files/Final%20version%20of%20Background%20Review%20on%20Relative%20Effectiveness%20Assessment%2Bappendix.pdf (accessed September 19, 2013).Google Scholar
8. Pasternack, I, Anttila, H, Mäkelä, M, et al. Testing the HTA core model: Experiences from two pilot projects. Int J Technol Assess Health Care. 2009;25 (Suppl 2):21–27.CrossRefGoogle ScholarPubMed
9. EUnetHTA Joint Action 2 WP8. HTA Core Model® Online Handbook. Version 1.4. 17 Sep 2012 http://meka.thl.fi/htacore/ViewHandbook.aspx (accessed February 10, 2014).Google Scholar
10. High Level Pharmaceutical Forum. Core principles on relative effectiveness. 2008 http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/rea_principles_en.pdf (accessed September 19, 2013).Google Scholar
Supplementary material: File

Kleijnen et al. supplementary material

Table 1

Download Kleijnen et al. supplementary material(File)
File 44 KB